EMG
SRPT icon

Ellington Management Group’s Sarepta Therapeutics SRPT Stock Holding History

Ellington Management Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,400
Closed -$213K – 773
2019
Q2 		$213K Buy
+1,400
New +$170K 0.04% 473
2018
Q3 		– Sell
-3,100
Closed -$410K – 661
2018
Q2 		$410K Buy
+3,100
New +$292K 0.03% 209
2016
Q4 		– Sell
-14,100
Closed -$866K – 783
2016
Q3 		$866K Buy
+14,100
New +$426K 0.24% 93

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Ellington Management Group's SRPT Position: Q3 2019 in Review

Ellington Management Group sold out of Sarepta Therapeutics (SRPT) in Q3 2019, closing a stake of 1,400 shares — an estimated $213K sold.

Ellington Management Group first reported a position in SRPT in Q3 2016 and held it in 3 quarters. The position peaked at $866K in Q3 2016. 340 funds tracked by Wall St. Rank hold SRPT as of Q3 2019.

  • Ellington Management Group reported no remaining Sarepta Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Ellington Management Group sold 1,400 Sarepta Therapeutics shares in Q3 2019, an estimated $213K.
  • Ellington Management Group first reported a position in Sarepta Therapeutics in Q3 2016 and held it in 3 quarters.
  • Ellington Management Group's Sarepta Therapeutics position peaked at $866K in Q3 2016.
  • 340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2019.

Based on Ellington Management Group's 13F filing for Q3 2019, filed 14 Nov 2019.